// App-Quantinova.ai

18609 : Cost-effectiveness of Apixaban Against Dabigatran and Rivaroxaban for Stroke Prevention in Non-valvular Atrial Fibrillation Patients

Researchers

Presenter

  • Tereza Lanitis

Principal Investigators

  • Thitima Kongnakorn

  • Hemant Phatak

  • Larry Z Liu

  • John Lawrence

  • Paul Dorian

Medical Centers

  • U Toronto, Toronto, ON, Canada

  • University of Birmingham, Birmingham, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • Pfizer Inc.

  • Evidera, Inc.

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Non-valvular atrial fibrillation

  • Myocardial infarction

  • Arrhythmia

  • Intracerebral hemorrhage

  • Ischemic stroke

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Pradax

  • apixaban

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved